Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 21, 2021 4:31pm
236 Views
Post# 34151040

RE:Cancer treatment is on forefront in US

RE:Cancer treatment is on forefront in USThey're using the DARPA/Internet example whicn sounds great but isn't that easy.  I've never felt there isn't already a very high commercial incentive for exploring cures for hard to treat diseases.  It's just that it takes time.  mRNA research started in 1989, so it wasn't really used for the first 30 years while it was perfected.

The problem with partnering with somethiing like this is they will want some ownership, which THTX will not want to give them because their actual science is already understood and being tested. Further, THTX is actually moving pretty darn fast with the SORT1 platform in my view and doesn't really need outside money to complete the Phase 1 and start in to a Phase 2 possibly.  Maybe the ATM offering or something else occurs once the science and commercial potential is clearer to the market. Raising money should be easy if there's a POC coming.


JayjayUSA12007 wrote:
https://degette.house.gov/media-center/press-releases/degette-upton-introduce-highly-anticipated-cures-20-bill

This agency should be informed of Thera efforts on Sortilin. It would either partner or fund the effort to speed up development.


<< Previous
Bullboard Posts
Next >>